Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Sarcoma Channel is supported with funding from Iovance Biotherapeutics (Silver).

VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

ASCO 2023 | Alliance A091902: cabozantinib + nivo for advanced angiosarcoma previously treated with a taxane

Juneko Grilley-Olson, MD, Duke University, Durham, NC, discusses the promising results of the Phase II Alliance A091902 (NCT04339738) trial investigating the combination of cabozantinib and nivolumab for patients with locally advanced/metastatic angiosarcoma who had previously received taxane chemotherapy. The study enrolled patients who were not restricted on the number of prior lines but had not received prior anti-VEGF and immunotherapies. The combination therapy showed significant antitumor activity, with an objective response rate (ORR) of 62%, including responses in both cutaneous and noncutaneous disease subtypes. The treatment was well-tolerated without new safety concerns. The study highlights the potential of the cabozantinib and nivolumab combination in angiosarcoma subtypes, offering a new therapeutic option for patients with angiosarcoma pretreated with taxane. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Annual Congress in Chicago, IL.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

Choose your cookie settings

VJOncology uses necessary cookies to make the site work. With your permission we'd also like to use analytics, preference and marketing cookies to understand how the site is used and improve it.

Choose an option to continue. You can change it at any time on our Cookie Policy page, linked at the bottom of every page.